Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Placebo Controlled, Double Blind, Randomised, 8-week Phase IIa Proof of Concept Study to Assess the Efficacy and Safety of AKR 202 in Patients With Osteoarthritis Pain

NCT02003118 is registered in ClinicalTrials.gov with Akron Molecules AG as lead sponsor.

NCT NCT02003118
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02003118 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Placebo Controlled, Double Blind, Randomised, 8-week Phase IIa Proof of Concept Study to Assess the Efficacy and Safety of AKR 202 in Patients With Osteoarthritis Pain
Lead sponsor
Akron Molecules AG
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2013
Completion date
July 31, 2014
Enrollment
266 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

osteoarthritis